Happiest Minds Tech collaborates with AutonomIQ; stock tanks
Happiest Minds Tech collaborates with AutonomIQ; stock tanks

Happiest Minds Tech collaborates with AutonomIQ; stock tanks

Ganesh V Article rating: 3.6

Happiest Minds Technologies Ltd and AutonomIQ announced a partnership to accelerate the enterprise digital transformation journey using autonomous testing capabilities.

Alembic Pharma receives one more ANDA
Alembic Pharma receives one more ANDA

Alembic Pharma receives one more ANDA

Rishikesh Gaikwad Article rating: 3.5

Alembic Pharmaceuticals Limited announced during the first half of the trading session (at around 10 am to be specific) that it has received tentative approval from United States Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Palbociclib capsules, 75 mg, 100 mg, and 125 mg. 

Blue Star share rises on winning order worth Rs 128 crore
Blue Star share rises on winning order worth Rs 128 crore

Blue Star share rises on winning order worth Rs 128 crore

Chinmayee D Article rating: 3.2

Blue Star Limited is experiencing a gradual increase in the inflow of orders for bundled services. Presently, this order is one of the largest and fast-track projects, which is being executed by Blue Star in the factories’ segment.

Dilip Buildcon emerges as lowest bidder; stock gains
Dilip Buildcon emerges as lowest bidder; stock gains

Dilip Buildcon emerges as lowest bidder; stock gains

Chinmayee D Article rating: 3.0

The mineable reserve block is 1,091 million metric tonnes, which is to be exploited for a period of 25 years at a peak rated capacity of 50 million tonnes per annum.

Balkrishna Industries: Volume jumps 61 per cent QoQ in Q2FY21
Balkrishna Industries: Volume jumps 61 per cent QoQ in Q2FY21

Balkrishna Industries: Volume jumps 61 per cent QoQ in Q2FY21

Nidhi Jani Article rating: 4.7

On the volumes’ front, the company reported the highest-ever quarterly sales volume in Q2FY21. Besides, it registered a significant jump of 60.71 per cent QoQ to 61,224 MT in Q2FY21 vs 38,096 in Q1FY21.

Biocon share rises more than 4 per cent on receiving Rs 1,125 crore investment from Goldman Sachs
Biocon share rises more than 4 per cent on receiving Rs 1,125 crore investment from Goldman Sachs

Biocon share rises more than 4 per cent on receiving Rs 1,125 crore investment from Goldman Sachs

Ganesh V Article rating: 3.8

Biocon Ltd announced that the board of its subsidiary, Biocon Biologics Ltd has approved a capital injection of Rs 1,125 crore from Goldman Sachs on Saturday. Under the terms of the agreement, Goldman Sachs will be issued optionally convertible debentures at a post-money equity valuation of USD 3.94 billion.

Five stocks with buying interest
Five stocks with buying interest

Five stocks with buying interest

Ganesh Pawar Article rating: 4.2

The market opened in green on November 09, 2020, overall volumes in futures & options currently stand at 1,90,93,884 contracts with a turnover of Rs. 14,51,060.02 crore.

Five stocks with selling interest
Five stocks with selling interest

Five stocks with selling interest

Ganesh Pawar Article rating: 4.7

The market opened in green on November 09, 2020, overall volumes in futures & options currently stand at 1,90,93,884 contracts with a turnover of Rs. 14,51,060.02 crore.

IPO Analysis: Gland Pharma
IPO Analysis: Gland Pharma

IPO Analysis: Gland Pharma

Henil Shah Article rating: 3.5

Gland Pharma, a pharmaceutical company focussed on generic injectables, is hitting the primary capital market with its IPO today. Read on to find out if you should subscribe to the issue.

RSS
First20512052205320542056205820592060Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR